Built for every deployment. Built to defend.
Four deployment modes, native specialty capabilities, and a moat designed to compound. BioCompute meets you where your regulatory posture demands — SaaS to air-gapped — and ships with intoDNA STRIDE® integrated on day one.
The Problem
One deployment shape doesn't fit life sciences.
Different life-sciences customers operate at different regulatory postures. A research lab needs velocity; a CRO needs validation; a Tier-1 pharma running clinical trials needs sovereignty; a defense-adjacent biotech with classified IP needs air-gap. Generic AI platforms force a single deployment model and force the customer to compromise on either velocity, control, or compliance. Specialty capabilities — like single-molecule DNA damage detection — require scientific partnerships that generic clouds cannot replicate. And buyers also need to see the moat: why this platform compounds in value over time.
- 1
One-size-fits-all SaaS forces regulated customers to accept governance compromises that fail audit.
- 2
Pure on-premise / air-gap deployment forfeits the velocity and ecosystem of cloud-native infrastructure.
- 3
Specialty scientific capabilities (DDR biomarkers, single-molecule detection, validated assay-to-submission chains) require partnerships generic cloud providers cannot pre-integrate.
- 4
Customers want to know the architecture is not just useful today — that it compounds in value as they expand, as regulators tighten, and as the AI ecosystem matures.
Deployment — four modes, one governance layer
Four modes. Same six components. Same audit chain.
BioCompute deploys in four modes. Each is chosen by the customer's regulatory posture. The same six native components and the same audit chain operate identically across every tier.
SaaS.
Multi-tenant, logically isolated. Fastest time-to-value. Research and pilot stage; lab-stage AI workflows.
Dedicated.
Single-tenant, bring-your-own-key, SOC 2 Type II. Production workloads; CRO and translational research deployments.
Customer Cloud.
AWS, Azure, or GCP, running in the customer's VPC as a closed system with FDA closed-system status. Production and submission-grade; pharma and clinical-research deployments.
Air-Gapped.
Zero egress, FIPS 140-2. Classified, precision-medicine IP, defense-adjacent biotech, and clinical settings with the strictest sovereignty requirements.
Customers move between deployment modes as their regulatory posture evolves. A research project that starts in SaaS can graduate to Dedicated when it enters validation, then to Customer Cloud for production submission, then to Air-Gapped if the IP profile demands. The same components, the same audit chain, the same evidence model — across the entire journey.
Native specialty — capabilities only available here
Specialty integrations that exist nowhere else.
Beyond the six native components, BioCompute ships with native specialty integrations — capabilities that exist nowhere else and that only make sense on governance-native infrastructure.
intoDNA STRIDE® is the first clinical-grade DNA damage response biomarker platform on sovereign AI. AstraZeneca-validated; published in NAR Cancer (2025 prostate-cancer combination study). Single-lesion sensitivity — sSTRIDE and dSTRIDE detect individual DNA breaks. AI foci detection governed natively by BioCompute's AI Gateway. Evidence chain from assay to submission via Evidence Engine + Evidence Packs. BioCompute is architected to absorb additional specialty partners over time — STRIDE today, more in 2026 and beyond.
Validation
AstraZeneca
Publication
NAR Cancer
Resolution
Single-lesion
Partner
NVIDIA Inception
The Moat — why BioCompute compounds
Four claims. Compounding over time.
Four claims that make BioCompute defensible long-term, in priority order.
Regulation by construction, not retrofit.
Every capability maps to a specific regulatory citation; the map deepens with every customer deployment and every new regulation.
Identical governance from SaaS to air-gapped.
Identical control plane, audit chain, and evidence integrity across SaaS, Dedicated, Customer Cloud, and Air-Gapped. Architectural choice on day one — cannot be bolted on by hyperscalers (wrong starting point for air-gap) or on-prem players (wrong cost model for SaaS).
Unbroken evidence chain from data to regulator.
BioCompute owns the audit trail from the assay instrument or clinical-data source, through every model decision, into the IND / NDA / BLA / PCCP filing. Once embedded, ripping it out doesn't lose a vendor — it breaks the customer's submission.
A growing ecosystem of specialty capabilities.
intoDNA STRIDE® today. Architected to absorb additional specialty partners over time. Each new partner makes the next one easier to land — because partners need governance-native infrastructure, and BioCompute is becoming the default substrate for life-sciences-specialty AI.
Compliance and framework mapping by deployment tier
Mapped per tier. Stacked across tiers.
All four tiers
SOC 2 Type II; ISO 27001; HIPAA; ISO 42001.
SaaS tier (additional)
Logical tenant isolation; multi-tenant audit segregation.
Dedicated tier (additional)
BYOK customer-controlled encryption keys; single-tenant isolation.
Customer Cloud tier (additional)
FDA closed-system status; GxP environments; data residency in customer-controlled VPC across AWS, Azure, GCP.
Air-Gapped tier (additional)
FIPS 140-2; defense-grade isolation; classified IP support.
Native STRIDE specialty
AstraZeneca validation; published peer-reviewed research; regulatory-ready outputs.
FAQ
Frequently asked
Continue exploring BioCompute
One platform. Three lenses.
Promise
Lab to regulated production. On one platform.
Components
Six components. One platform. Built for life sciences.
Deployment & Defensibility
Built for every deployment. Built to defend.